David Morris
Direttore/Membro del Consiglio presso Enterprise Therapeutics Ltd.
Provenienza dei contatti di primo grado di David Morris
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd
12
| Subsidiary | Investment Managers | 12 |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.
8
| Holding Company | Biotechnology | 8 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a David Morris tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Sorbent Therapeutics, Inc.
Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
Anchor Therapeutics, Inc.
Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ANNEXON, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Thesan Pharmaceuticals, Inc.
Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
GALERA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Zikani Therapeutics, Inc.
Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA. | Drugstore Chains | Chairman Director/Board Member | |
IP GROUP PLC | Miscellaneous Commercial Services | Corporate Officer/Principal | |
University of Leeds | College/University | Doctorate Degree Doctorate Degree | |
VITAE PHARMACEUTICALS INC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz. | Investment Managers | Private Equity Investor Private Equity Investor | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Consultant / Advisor Private Equity Analyst | |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Director/Board Member Private Equity Investor | |
AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Dartmouth Medical School | College/University | Doctorate Degree | |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Cogent Neuroscience, Inc. | Corporate Officer/Principal | ||
Science Club For Girls | Director/Board Member | ||
ALECTOR, INC. | Biotechnology | Director/Board Member | |
Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Pulmocide Ltd.
Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Merck Research Ventures
Merck Research Ventures Investment ManagersFinance Merck Research Ventures, a subsidiary of Merck Research Laboratories is a venture capital firm founded in 2000. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Oxular Ltd.
Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Vertex Ventures HC
Vertex Ventures HC Investment ManagersFinance Vertex Ventures HC (Vertex Ventures) is a venture capital subsidiary of Vertex Venture Holdings Ltd founded in 2014. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor | |
Redona Therapeutics, Inc.
Redona Therapeutics, Inc. BiotechnologyHealth Technology Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA. | Biotechnology | Director/Board Member Director/Board Member | |
TSCAN THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
ENTRADA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
BOUNDLESS BIO, INC. | Biotechnology | Director/Board Member | |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member Director/Board Member | |
Immunitas Therapeutics, Inc.
Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Tallac Therapeutics, Inc.
Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | Biotechnology | Director/Board Member | |
Pathway To Cures
Pathway To Cures Investment ManagersFinance Pathway To Cures (Pathway To Cures) is a venture capital firm founded in 2022. The firm is headquartered in New York. | Investment Managers | Investment Committee Member | |
Novartis Services, Inc. | President Corporate Officer/Principal Corporate Officer/Principal | ||
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Chief Operating Officer Director/Board Member |
Statistiche
Distribuzione geografica
Stati Uniti | 38 |
Regno Unito | 9 |
Canada | 2 |
Svizzera | 2 |
Germania | 2 |
Settori
Health Technology | 36 |
Finance | 6 |
Consumer Services | 4 |
Commercial Services | 3 |
Retail Trade | 2 |
Posizioni
Director/Board Member | 170 |
Corporate Officer/Principal | 51 |
Private Equity Investor | 27 |
Chief Executive Officer | 16 |
Chairman | 15 |
Contatti più connessi
Insiders | |
---|---|
Henry Skinner | 29 |
Amit Munshi | 27 |
Steve D. Weinstein | 23 |
Campbell Murray | 23 |
Bobby G. Soni | 23 |
Christine Brennan | 20 |
Alexander Mayweg | 18 |
Lauren Silverman | 18 |
Michal Silverberg | 17 |
Markus Goebel | 16 |
Giovanni A. Ferrara | 15 |
Peter Finan | 14 |
Laura Brass | 11 |
Juliette Audet | 11 |
John W. Ford | 10 |
- Borsa valori
- Insiders
- David Morris
- Connessioni Società